Institutional Biosafety Committee (IBC)

An IBC is required for institutions receiving funding from the National Institutes of Health (NIH) for research involving recombinant or synthetic nucleic acid molecules. 

You must register your research with the IBC if it involves any of the following:

  1. recombinant or synthetic nucleic acid molecules as described by the NIH Guidelines,
  2. human materials such as blood, cells, or tissue,
  3. infectious agents, or potentially pathogenic material.

IBC protocols are currently submitted and managed in the CICERO online system. The IBC will review your submission and advise you of its findings.

The IBC meets monthly, usually on the first Friday of every month. The submission deadline for inclusion in a meeting is approximately two weeks before the meeting. Please see the IBC Calendar for exact dates. 

More information on IBC procedures can be found in the IBC Charter.

Key IBC Personnel


Biosafety Officer and NIH Contact

Dr. Matthew Fischer

IBC Analyst

John O’Neill

IBC Analyst

Jamie Pope

 

 

 

Institutional Official (IO)

Dr. Bruce Jarrell

Related Links